东诚药业：氟[18F]思睿肽注射液上市申请获受理

Core Viewpoint - Dongcheng Pharmaceutical's subsidiary, Lanacheng, has received approval from the National Medical Products Administration for the marketing application of the investigational drug Fluorine-18 [18F] PSMA peptide injection, which targets PSMA for PET imaging in prostate cancer patients [1] Group 1: Product Information - Fluorine-18 [18F] PSMA peptide injection is a radiopharmaceutical used for in vivo diagnostic imaging targeting prostate-specific membrane antigen (PSMA) in prostate cancer patients [1] - There are currently no similar products available in the domestic market, while similar products are already available internationally [1] Group 2: Market Context - Lantheus Holdings reported that its product, 18F-PSMA diagnostic agent PYLARIFY, is expected to generate sales revenue of $1.1 billion in 2024 [1]